US Capitol Capsule: Rare Diseases: The Path To Precision Medicine
This article was originally published in Scrip
The path to achieving the promise of precision medicine – prevention and treatment strategies that take individual variability in genes, environment and lifestyle into account – must go through the discovery, research and development processes of rare diseases, a panel of experts and advocates said last week during a Capitol Hill briefing hosted by the House Rare Disease Congressional Caucus, headed by Reps. Leonard Lance (R-NJ) and Joe Crowley (D-NY).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.